Smith & Nephew (SN) Investor presentation summary

Market positioning and portfolio

• Operates in markets worth approximately $50bn, growing at 6% annually, with leading positions in Advanced Wound Management, Orthopaedics, Sports Medicine, and ENT.

• Holds #2 share in Advanced Wound Management (13%) and Sports Medicine (25%), #4 in Orthopaedics (7%) and ENT (9%).

• Diversified 2025 revenue split: Orthopaedics 39%, Sports Medicine 28%, Advanced Wound Management 29%, ENT 4%.

Strategic execution and transformation

• Completed a 12-Point Plan, addressing product availability, operational efficiency, and commercial execution.

• Shifted to a business unit-led structure, increasing accountability and customer focus, with cost savings and disciplined capital allocation.

• Achieved 5.7% revenue CAGR (2022-2025), 240bp trading margin increase, and 15x FCF growth.

RISE strategy and innovation

• Launched RISE strategy: Reach more patients, Innovate, Scale through investment, Execute efficiently.

• Acquired Integrity Orthopaedics for up to $450m, expanding the shoulder portfolio with innovative products like Tendon Seam.

• Robust pipeline with increased product launches planned for 2026-2028 across all business units.